SPRB
SPRUCE BIOSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$40.40
+1.89%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$39.64
From 52W high−74.40%
Volume57098.00
Market cap$116.11M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$39.64
From 52W high
−74.40%
Volume
57098.00
Market cap
$116.11M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
37.2
MomentumView details →
1D Return
+1.89%
YTD Return
−53.16%
SummaryUpdated Jun 1, 2026
Spruce Biosciences, Inc. (NASDAQ:SPRB) is a biopharmaceutical company founded in 2014 and headquartered in Daly City, California. The company went public in October 2020 and has undergone a significant strategic transformation. Originally focused on developing treatments for congenital adrenal hyperplasia (CAH), Spruce pivoted in 2024 to acquire and develop Tralesinidase Alfa, an enzyme replacement therapy for a rare pediatric neurodegenerative disease called MPS IIIB (Mucopolysaccharidosis IIIB or Sanfilippo syndrome type B).
Similar companies
Latest newsMore news →
Spruce Biosciences launched MPS3BStudy.com, an online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB), enabling them to learn about and register interest in a related study.54d agoSpruce Biosciences hired Adrian Quartel as chief medical officer.59d agoCure Sanfilippo Foundation and the National MPS Society agreed to make a combined $5.5 million strategic investment in Spruce Biosciences.68d ago